Navigation Links
Pro Bono Bio Announces the Successful Development of Subcutaneous and Long-Acting Blood Factors VIIa,VIII and IX for the Treatment of Haemophilia
Date:9/10/2012

LONDON and MOSCOW, September 11, 2012 /PRNewswire/ --

Subcutaneous blood factors expected to revolutionise the treatment paradigm of haemophiliac patients worldwide

Pro Bono Bio Group plc ("PBB"), the international healthcare group, announces the successful conclusion of a series of pre-clinical trials in haemophiliac subjects conducted with the world's first long acting blood Factors VIIa, VIII and IX capable of subcutaneous administration. The results of these trials are of great importance as these novel long-acting, subcutaneous blood factors are expected to revolutionise the treatment paradigm for haemophilia sufferers worldwide. The availability of PBB's subcutaneous blood factors would make self-administration by patients at home much easier leading to a significant improvement in treatment compliance and reduction in healthcare system costs by avoiding the need for regular IV infusions.

Key findings from the 8 trials with 6 products conducted at the University of Alabama were:

  • PBB's current subcutaneous form of FVIIa achieved up to 3 days of haemostatic cover providing the prospect of sustained prophylactic treatment for haemophilia A patients who suffer an immune response to FVIII meaning that FVIII is no longer a viable therapy for them.
  • PBB's current intravenous form of Factor VIIa achieved a 12x extension of haemostasis over current commercially available products. This means it could offer significant advantages in trauma applications in hospitals where haemostatic cover can be maintained for the duration of long operations and post-operation, without the current need for multiple administrations and related complications.
  • PBB's subcutaneous form of Factor VIII for haemophilia A achieved a circulating dose level of 20% of the intravenous version and also maintained haemostasis for 72 hours, meaning that it is already suitable for twice-weekly dosing a
    '/>"/>

SOURCE Pro Bono Bio
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... 2015 , ... Graphite Metallizing Corporation, the manufacturer of self-lubricating ... of Dennis Rawle as European Director of Sales. Rawle has over 25 years ... Manager and Technical Sales Manager for pump products at Exalto UK. Rawle will ...
(Date:8/4/2015)... , August 4, 2015 ... Allied Market Research, titled, "World Cardiac Biomarker - ... biomarker market would generate the revenue of $2,085.9 ... from 2015 to 2020. Cardiac Troponins (T, I) ... forecast period due to high sensitivity and specificity. ...
(Date:8/4/2015)... , Aug. 4, 2015 Trigemina, Inc., ... of non-narcotic, nasally delivered, analgesic drug products, announced today ... to the position of chief medical officer. Dr. Kori ... Trigemina, much of which has been focused in the ... to add Dr. Kori to our clinical team given ...
(Date:8/4/2015)... ... August 04, 2015 , ... RPS ... tests – today announced that Robert A. Gregg, PhD, has joined RPS as ... 30 years of relevant experience and remarkable achievements in the medical device and ...
Breaking Biology Technology:Dennis Rawle Joins Graphite Metallizing Corporation 2Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 2Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 3Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 4Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 5Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 2Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 3RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 2RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 3
... Advanced Instruments, Inc . today introduced the ... automation-friendly osmometer for the biopharmaceutical industry."The ... designed for -- and completely redefines -- automation ... said Kelly Peterson, Product Manager, Advanced Instruments ( ...
... announced today,promising findings on the in vitro ... cancer developed on the basis of its ... both in vitro and in vivo models,Santaris ... inhibition of disease-associated microRNAs due to their ...
... April 20 Psylin Neurosciences Inc., ... Amylin Pharmaceuticals, Inc. and PsychoGenics, Inc. announced today ... novel compound, PSN0041, for the treatment of depression.(Logo: ... )PSN0041, a peptide from Amylin,s proprietary polypeptide hormone ...
Cached Biology Technology:Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry 2Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry 3LNA-Based RNA oligonucleotides Potently Inhibit Cancer microRNAs 2Psylin Neurosciences Commences Development of Compound for Depression 2Psylin Neurosciences Commences Development of Compound for Depression 3
(Date:8/4/2015)... ) today reported financial and operating results for the second quarter ... quarter contract revenue of $ 85.2 million, a ... of 26 % , Second quarter adjusted ... royalties in the current quarter , Operating cash ... to present another strong financial quarter, with all our divisions achieving ...
(Date:8/3/2015)... SAN JOSE, Calif. , Aug. 3, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that members ... investment community at the Pacific Crest Global Technology Leadership ... Mountain Time. The conference will be held at the ... The presentation may include forward-looking information. ...
(Date:7/31/2015)... -- Den 10. internationale konference om Genomik (ICG-10, ... 25. oktober i Shenzhen , Kina. ... år. Siden starten i 2006 er ICB blevet en ... er en af de mest dynamiske, entusiastiske og sjove ... gennembrud og fremskridt inden for ,omik,-forskning, som yderligere vil ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... In a discovery that seems counterintuitive, a study appearing ... has found that tendons in high-stress and strain ... frequently than low-stress tendons. This study sheds some light ... during aging. Tendons, composed of collagen and other ...
... a defect in cellular pathways that provides a new explanation ... known as craniosynostosis. Mutations of the WNT and ... regulate bone formation at the stem cell level, according to ... Science Signaling . "Our work contributes to the overall ...
... Rensselaer Polytechnic Institute and principal investigator Glenn Monastersky have been ... Stem Cell Science Program (NYSTEM) of the Empire State Stem ... the Center for Biotechnology and Interdisciplinary Studies (CBIS), said the ... excellence for basic stem cell research within the CBIS. ...
Cached Biology News:High-strain tendons repair less frequently 2Stem-cell disruption induces skull deformity, UR study shows 2Rensselaer Polytechnic Institute wins $2.45 million grant to support stem cell research 2
Contains L-glutamine...
... the 11(R)-LOs of the sea urchin, ... hydra, H. vulgaris. The biological activity ... and tentacle regeneration, respectively, in these ... aspirin-treated recombinant COX-2 is incubated with ...
Rabbit anti-T-box 6...
karyopherin alpha2 (2G7)...
Biology Products: